

# NEUROIMAGING AND CSF BIOMARKER PROGRAM

## FUNDING OPPORTUNITY DESCRIPTION

The aim of this RFP is to further develop and validate established biomarkers for which there is a clear clinical need in Alzheimer's disease and related dementias. This RFP prioritizes biomarkers with a **defined context of use**, a clear advantage over other relevant biomarkers, and a path to commercialization and/or clinical use.

Specifically, this RFP focuses on:

- Developing novel PET ligands for clinical trials
- Supporting novel CSF biomarkers
- Validating innovative MRI approaches in larger cohorts
- Developing novel measures of functional activity such as EEG

*Peripheral biofluids and digital/ocular approaches are supported through the [Diagnostics Accelerator RFP](#).*

**Novel biomarkers of neuroinflammation, synaptic integrity, autophagy and TDP-43 are high priority. Other target areas of interest include:**

- Neuronal loss
- Vascular injury and blood-brain barrier integrity
- Mitochondria and metabolic function
- Protein misfolding
- Oxidative stress
- White matter changes
- Lewy body dementia
- Other novel targets supported by compelling biological rationale and connection to disease

*The ADDF has limited interest in CSF measures of amyloid and tau.*

## UPCOMING DEADLINES

**ELIGIBILITY**

**AWARD INFORMATION**

**FUNDING PRIORITIES**

**EXPECTATIONS AND EVALUATION**

## **APPLICATION SUBMISSIONS**

Review the [Application Instructions](#) for steps on applying.

**LOG IN OR CREATE ACCOUNT**

**We encourage you to contact us if you would like to discuss your proposed project and receive initial feedback.**

**For scientific inquiries, please contact:**

**Meriel Owen, PhD, Associate Director, Scientific Affairs**

**[mowen@alzdiscovery.org](mailto:mowen@alzdiscovery.org)**

**For inquiries related to contracting and the online funding portal, please contact:**

**Mission Related Investments Team**

**[grants@alzdiscovery.org](mailto:grants@alzdiscovery.org)**